Legend Biotech Corp
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $LEGN in the last 7 days.
H.C. Wainwright reiterated a Buy rating and $65 price target for Legend Biotech (LEGN) due to strong Carvykti sales. Q3 2026 sales reached $710M, exceeding expectations. Revenue estimates were raised for 2026 and 2027. The stock trades at $19.04, below the price target and fair value estimate.
JPMorgan reduced its price target for Legend Biotech (LEGN) to $33 from $35, maintaining a Neutral rating. The firm cited unspecified reasons for the adjustment. This follows recent insider activity and clinical data announcements by the company.
Legend Biotech (LEGN) reported five-year data from the CARTITUDE-2 trial, showing 50% of relapsed or refractory multiple myeloma patients alive and progression-free without maintenance after a single CARVYKTI infusion. The results strengthen CARVYKTI's clinical staying power and potential treatment positioning. The company reported a net loss of $91.5 million on $1.27 billion revenue, with analysts projecting 19.0% yearly revenue growth and a shift to positive net income by 2029.
Recent LEGN coverage spans financial news, earnings and insider activity.
In the last 30 days, LEGN insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($259K). The most active reporter was Sanders Corazon (Corsee) D. with 1 filing.
Analyst upgrade with a high price target versus current price.
Analyst price‑target reduction suggests lower near‑term upside.
Positive long‑term efficacy data could boost investor confidence and lift the stock.
The insider sale may create modest downward pressure on the stock.
The durable remission data could boost investor confidence and support a higher valuation for Legend Biotech.
AlphAI scores every news story that mentions LEGN with an AI model for sentiment and relevance, and aggregates insider trades from Legend Biotech Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
H.C. Wainwright reiterated a Buy rating and $65 price target for Legend Biotech (LEGN) due to strong Carvykti sales. Q3 2026 sales reached $710M, exceeding expectations. Revenue estimates were raised for 2026 and 2027. The stock trades at $19.04, below the price target and fair value estimate.
2 min readJPMorgan reduced its price target for Legend Biotech (LEGN) to $33 from $35, maintaining a Neutral rating. The firm cited unspecified reasons for the adjustment. This follows recent insider activity and clinical data announcements by the company.
1 min readLegend Biotech (LEGN) reported five-year data from the CARTITUDE-2 trial, showing 50% of relapsed or refractory multiple myeloma patients alive and progression-free without maintenance after a single CARVYKTI infusion. The results strengthen CARVYKTI's clinical staying power and potential treatment positioning. The company reported a net loss of $91.5 million on $1.27 billion revenue, with analysts projecting 19.0% yearly revenue growth and a shift to positive net income by 2029.
3 min readSanders Corazon (Corsee) D. sold 27,370 shares of Legend Biotech Corp (LEGN) at $9.46 ($0.26M total) on 2026-09-29.
1 min readLegend Biotech (LEGN) reported five-year data from CARTITUDE-2 showing 50% of patients with earlier-line multiple myeloma remained progression-free after a single CARVYKTI infusion. The study, presented at the 2026 IMS Annual Meeting, showed a 69.2% overall survival rate, reinforcing CARVYKTI's potential for durable remission. CARVYKTI is a BCMA-directed cell therapy developed in collaboration with Janssen Biotech.
2 min readLegend Biotech (LEGN) reported $657M in Q2 2026 CARVYKTI sales, up 50% YoY, with global expansion. The company has $965M in cash and appointed Ingrid Zhang as CEO. Challenges include operational bottlenecks and tax uncertainties. LEGN trades at a forward P/E of 27.55.
3 min readLegend Biotech Corp. (LEGN) named Ingrid Zhang as CEO, effective September 15. Zhang succeeds Alan Bash, who will return to his role as President of Carvykti. Zhang previously served as Chief Commercial Officer at Novartis. The company aims to advance its pipeline and execute long-term growth strategies. LEGN stock is up 2.70% in pre-market trading at $19.03.
1 min readLegend Biotech (LEGN) highlighted its CAR-T therapy CARVYKTI for multiple myeloma, expanding manufacturing, and in vivo CAR-T approaches. The company projects $2.2B revenue and $464.7M earnings by 2029, requiring 20.2% yearly revenue growth. Analysts caution about concentration risks and competition.
3 min readLegend Biotech (LEGN) reported Q2 2026 revenue of $387.5M, up from $255.1M, and net income of $33.2M, reversing a prior loss. H1 2026 revenue was $692.6M, with net loss reduced to $21.1M. The company projects $2.2B revenue and $464.7M earnings by 2029. Analysts highlight CARVYKTI's role in profitability and pipeline assets. Management changes and CARVYKTI's dominance remain key risks.
2 min readLegend Biotech (LEGN) reported Q2 2026 revenue of $387.5M and net income of $33.2M, reversing a year-earlier loss. The stock has declined 38.5% over 1 year and 68.3% over 3 years, but is up 1.9% year-to-date. Analysts suggest the stock may be undervalued at $21.92, with a fair value estimate of $54.23, citing growth potential in multiple myeloma treatments and expansion opportunities.
3 min read
